Zhaoke Ophthalmology Partners with Yidu Tech’s HappyLife Tech to Accelerate the Development of Innovative Clinical Research for the Chinese Ophthalmic Market

HONG KONG,16 December2021– Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, and Yidu Tech Inc. (“Yidu Tech”, SEHK: 2158), a healthcare big data and artificial intelligence solutions provider,  are pleased to announce today that Zhaoke Ophthalmology and Tianjing HappyLife Technology Limited (“HLT”), an affiliate of Yidu Tech  that provides life sciences solutions, have signed a Letter of Intent (LOI), with an objective to accelerate the development of innovative clinical research programs for the Chinese ophthalmic market, in order to jointly deliver better medical care and support to eye disease patients in China.

According to the LOI, the partnership between Zhaoke Ophthalmology and HLT will initially focus on the following three areas:

·      Nurturing talent for clinical research

The two parties will provide clinical research education programs to healthcare professionals at the clinical trial centres, with an aim to further good clinical trial practices and understanding.

·      Building a clinical research network

The two parties will leverage their resources and build a joint clinical research network, with the aim to improve product development efficiency and lifecycle maintenance optimization.

·      Developing a digitalized clinical research model

With the help of Zhaoke Ophthalmology’s strong research and development capability in ophthalmic drugs and HLT’s technological expertise, the two parties will work together to help transform the clinical research model into a more digital one. This will lead to initiatives such as introducing virtual clinical trials, with the aim to improve clinical trial performance.

Dr. Li Xiaoyi (Benjamin), Chairman and CEO of Zhaoke Ophthalmology, said, “Favorable policies have been encouraging and supporting the innovative development of the pharmaceutical industry, especially the ophthalmic market, as part of China’s digital economy. As one of the leading ophthalmic pharmaceutical companies in China, we are very honored to partner with Yidu Tech and its life science solution unit HappyLife Tech, to further enhance and optimize the clinical research environment of the industry. We strongly believe that by leveraging Zhaoke Ophthalmology and HappyLife Tech’s strong R&D capabilities and vast resources in the ecosystem, we will be able to facilitate the digital development and construction of ophthalmology clinical research in China, thus providing better medical solutions for patients.”

Ms. Gong Yingying (Rujing), Chairlady, CEO and Founder of Yidu Tech said, “The strategic partnership with Zhaoke Ophthalmology is another important milestone for Yidu Tech in life sciences innovation and applications. ‘Value-based precision healthcare accessible to everyone’ is the mission of Yidu Tech. We are a strong believer in the value of AI technology to enhance the medical industry and we will continue to invest in it, to support the improvement of people’s health and wellbeing in China.”

Mr. Xu Jiming, Co-founder and Senior Vice President of Yidu Tech, and CEO of HappyLife Tech, said, "HappyLife Tech is committed to providing patients with truly personalized healthcare, working with partners to create an integrated ecosystem that provides full support in the patient’s journey from diagnosis to treatment. The cooperation between HappyLife Tech and Zhaoke Ophthalmology is an important step to implement this strategy. I believe that this partnership will enable both parties to build and share values in the field of clinical research, and to benefit more patients by continuously driving the development of the healthcare industry.”

About Yidu Tech Inc

Founded in 2014, Yidu Tech Inc. ("Yidu Tech", stock code: 2158.HK) focuses on the research, development and application of AI and big data technology for the healthcare industry. With a vision of "data intelligence and green healthcare", the Group focuses on solving the pain points of intelligent applications in three major healthcare scenarios of public health, research, and diagnosis and treatment, empowering the industry through data intelligence infrastructure, and promoting the construction of a safe, accessible, and value-based healthcare system. In January 2021, Yidu Tech was successfully listed on the Hong Kong Stock Exchange.

Yidu Tech primarily operates in three business segments, namely Big Data Platform and Solutions, Life Sciences Solutions, and Health Management Platform and Solutions, which facilitate medical research, healthcare management, public health management and development of innovative drugs, as well as assist the industry to reduce cost and improve efficiency, with an aim to make precision healthcare accessible to everyone.

About HappyLife Tech

HappyLife Tech (HLT) isanaffiliated company of China leading medical AI technology explorer Yidu Tech Inc. (SEHK: 2158). By leveraging the big data platform network of Yidu Tech, the life science solutions provided by HappyLife Tech integrate the deep disease knowledge and fledged team experiences to develop the digital applications and provide clinical research services to construct the platform network. HappyLife Tech is capable of providing innovative solutions and clinical trial services with quality, with the dedicated efforts to facilitate the digitalization transformation of clinical research.

About Zhaoke Ophthalmology

Founded in 2017, Zhaoke Ophthalmology (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapies that address significant unmet medical needs in the world. The company was listed in the Main Board of the Hong Kong Stock Exchange on 29 April 2021.

Zhaoke Ophthalmology has a comprehensive drug portfolio of 25 innovative and generic treatments covering five major eye diseases across both the front and back of the eye. Many of the drugs are being produced in its state-of-the-art and fully functional development and production facility in Nansha, Guangzhou.

Through its ambitious growth strategy, including partnering with domestic and international pharmaceutical companies, Zhaoke Ophthalmology’s goal is to become a leader in the world.

Zhaoke Ophthalmology has received strong endorsement from blue-chip pre-IPO investors, including GIC, Hillhouse Capital, TPG, Loyal Valley Capital, OrbiMed, Aier Eye Hospital and FountainVest. The Company recently completed its HK IPO with cornerstone investors including CaaS Capital, GIC, Golden Valley, Jennison, Mass Ave, Matthews Asia, OrbiMed and VMS Investment. For more details, please visit: www.zkoph.com.